Hydrocortisone Topical Spray 1%

Hydrocortisone Topical Spray 1%
Product Description

Used in topical treatment of skin inflammation of various origins, mainly allergic, of moderate intensity that react toglucocorticosteroids.

Used in the following indications:
•atopic dermatitis;
•allergic contact eczema;
•reactions following insect bites or stings (such as itching and irritation).


If there is no improvement or the patient feels worse after 7 days of product use, the product should be discontinued.

Read more Show less

A.forall Group

  • BE
  • 2022
    On CPHI since
  • 1
    Certificates
  • 100 - 249
    Employees
Company types
Generics/Biosimilars Manufacturer
Pharmaceutical company
Primary activities
Generic APIs producer
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Regulatory Affairs
View company profile
Categories
more categories Show less
Specifications
  • Details
    Topical Spray, Aluminium container 110ml (38,25g), Corticosteroids 
More specifications Fewer specifications

A.forall Group

  • BE
  • 2022
    On CPHI since
  • 1
    Certificates
  • 100 - 249
    Employees
Company types
Generics/Biosimilars Manufacturer
Pharmaceutical company
Primary activities
Generic APIs producer
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Regulatory Affairs
View company profile

More Products from A.forall Group (8)

  • Sumatriptan solution for injection in autoinjector 6mg/0,5 (single dose)

    Product Sumatriptan solution for injection in autoinjector 6mg/0,5 (single dose)

    Subcutaneous sumatriptan has been considered as the most efficacious treatment in the acute phase of migraine both on pain alone as well as on associated autonomic symptoms.
  • Edoxaban filmcoated tablets 15mg, 30 mg & 60 mg

    Product Edoxaban filmcoated tablets 15mg, 30 mg & 60 mg

    Edoxaban is indicated in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA). 

    ...
  • Fluticasone Furoate nasal spray 27.5 mcg/dose

    Product Fluticasone Furoate nasal spray 27.5 mcg/dose

    It is indicated in adults, adolescents and children (6 years and over)

    It is indicated for the treatment of the symptoms of allergic rhinitis.

  • Dexmedetomidine ready to use, 4mcg/ml (vial)

    Product Dexmedetomidine ready to use, 4mcg/ml (vial)

    For sedation of adult ICU (Intensive Care Unit) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).
    For sedation of non-intubated adult patients prior to and/or during diagnostic or surgical ...
  • Loperamide 2mg Orally Dispersible Tablets

    Product Loperamide 2mg Orally Dispersible Tablets

    For the symptomatic treatment of acute diarrhoea of any aetiology including acute exacerbations of chronic diarrhoea for periods of up to 5 days in adults and children over 9 years.

    For the symptomatic treatment of chronic diarrhoea in adults.
  • Tranexamic acid solution for injection 100mg/ml (Ampoules)

    Product Tranexamic acid solution for injection 100mg/ml (Ampoules)

    Prevention and treatment of hemorrhages due to general or local fibrinolysis in adults and children from one year.

    Specific indications include:

    - Haemorrhage caused by general or local fibrinolysis such as:

    - Menorrhagia and metrorrhagia,

    - Gastrointestinal blee...
  • Neomycin Topical Spray, 11,72mg/ml

    Product Neomycin Topical Spray, 11,72mg/ml

    Short-term topical use to treat bacterial skin infections, minor wounds (scratches, abrasions and afterinsect bites), minor ulcers and burns.
  • Azelastine+Fluticasone nasal spray 137/50 mcg/dose

    Product Azelastine+Fluticasone nasal spray 137/50 mcg/dose

    Relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.